Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
-1.79 (-0.99%)
4:00:02 PM EDT: $179.62 +0.01 (+0.01%)

Janssen says FDA Approved Cabenuva For Adolescents

Published: 03/30/2022 00:34 GMT
Johnson & Johnson (JNJ) - U.S. FDA Approves Cabenuva (cabotegravir and Rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-acting Injectable Hiv Regimen.
Janssen- Cabenuva is Approved As a Once-monthly Or Every-two-months Treatment for Hiv-1 in Virologically Suppressed Adults and Adolescents.